SELLAS Life Sciences
30 hedge funds and large institutions have $4.86M invested in SELLAS Life Sciences in 2024 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 1 reducing their positions, and 9 closing their positions.
10,387% more call options, than puts
Call options by funds: $7.45M | Put options by funds: $71K
1,200% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 1
0% more funds holding
Funds holding: 30 → 30 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
6.97% less ownership
Funds ownership: 14.03% → 7.06% (-7%)
38% less capital invested
Capital invested by funds: $7.82M → $4.86M (-$2.96M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$372K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$332K |
| 3 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$208K |
| 4 |
BlackRock
New York
|
+$207K |
| 5 |
Millennium Management
New York
|
+$205K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$4.88M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$26.8K |
| 3 |
PFG
Prosperity Financial Group
San Ramon,
California
|
-$25.6K |
| 4 |
CF
Cantor Fitzgerald
New York
|
-$25K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$17.6K |
SLS Hedge Fund Activity: Q2 2024 in Review
30 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q2 2024, worth a combined $4.86M — down 38% from $7.82M a quarter earlier.
Fund positioning in SLS was balanced in Q2 2024: 9 funds opened new positions, 9 closed out, 13 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, adding an estimated $372K. The largest seller was Anson Funds Management, exiting entirely with an estimated $4.88M sold.
- 30 institutional investors held SELLAS Life Sciences (SLS) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $4.86M of SELLAS Life Sciences stock for Q2 2024, down 38% quarter-over-quarter.
- 9 funds opened new SELLAS Life Sciences positions in Q2 2024 and 9 closed out, a net change of 0 holders.
- The largest SELLAS Life Sciences buyer in Q2 2024 was Vanguard Group, an estimated $372K added.
- The largest SELLAS Life Sciences seller in Q2 2024 was Anson Funds Management, an estimated $4.88M sold.
Based on aggregated 13F filings for Q2 2024.